Evidence map›Paper›PMID 29208654›Full record

ArticleDiabetes care2018

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes.

Juraj Koska, Aramesh Saremi, Scott Howell, Gideon Bahn, Barbora De Courten, Henry Ginsberg, Paul J Beisswenger, Peter D Reaven, VADT Investigators

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Juraj KoskaPhoenix VA Health Care System, Phoenix, AZ juraj.koska@va.gov.ORCID 0000-0002-6671-6250
Aramesh SaremiPhoenix VA Health Care System, Phoenix, AZ.
Scott HowellPreventAGE Healthcare, Lebanon, NH.
Gideon BahnHines VA Cooperative Studies Program Coordinating Center, Edward Hines Jr. VA Hospital, Hines, IL.
Barbora De CourtenMonash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-8760-2511
Henry GinsbergDepartment of Medicine, Columbia University, New York, NY.
Paul J BeisswengerPreventAGE Healthcare, Lebanon, NH.
Peter D ReavenPhoenix VA Health Care System, Phoenix, AZ.
VADT Investigators
Phoenix VA Health Care System · USPreventAGE Health Care (United States) · USColumbia University · USEdward Hines, Jr. VA Hospital · USMonash University · AU

Funding

Pathways of fenofibrate effects on cardiovascular outcomes in ACCORDR01HL110418 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2014
$2.0M
Diagnostic Biomarkers to Predict Individual Propensity to Diabetic ComplicationsR44DK101226 · NIDDK · PREVENTAGE HEALTHCARE, LLC · PI BEISSWENGER, PAUL · 2014 to 2016
$1.3M
NHLBI NIH HHS R01 HL110418NIDDK NIH HHS R44 DK101226
6 · The paper itself

Abstract

objectiveThe goal of this study was to determine whether plasma levels of advanced glycation end products (AGE) and oxidation products (OP) predict the incidence of cardiovascular disease (CVD) in type 2 diabetes. RESEARCH DESIGN AND

methodsFive specific AGE (methylglyoxal hydroimidazolone, carboxymethyl lysine, carboxyethyl lysine, 3-deoxyglucosone hydroimidazolone, and glyoxal hydroimidazolone) and two OP (2-aminoadipic acid and methionine sulfoxide [MetSO]) were measured at baseline in two intensive glucose-lowering studies:

resultsIncreased levels of several AGE and OP were associated with older age, decreased kidney function, previous CVD, and longer diabetes duration, but not with hemoglobin A

conclusionsLower levels of MetSO and higher levels of select AGE are associated with increased incident CVD and may help account for the limited benefit of intensive glucose lowering in type 2 diabetes.

Indexed as

2-Aminoadipic AcidAgedBody Mass IndexCardiovascular DiseasesCase-Control StudiesCholesterolCohort StudiesDeoxyglucoseDiabetes Mellitus, Type 2Glycated HemoglobinGlycation End Products, AdvancedHumansImidazolesIncidenceLysineMale2-Aminoadipic Acid3-deoxyglucosoneCholesterolDeoxyglucoseGlycated HemoglobinGlycation End Products, AdvancedImidazolesimidazoloneLysineMethioninemethionine sulfoxideN(6)-carboxyethyllysineN(6)-carboxymethyllysinePyruvaldehydeTriglycerides

Identifiers

PMID29208654
PMCPMC5829965
OpenAlexW2771721456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.